BeiGene: MCLA-129 is currently exploring indications in the field of lung cancer.

MET-2.84%
Jin10 data reported on August 19, Beida Pharmaceutical stated on the interactive platform that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met, currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will disclose any significant research progress in a timely manner.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
bbd®vip
· 2025-08-19 05:01
Just go for it💪
View OriginalReply0
bbd®vip
· 2025-08-19 05:00
Just go for it💪
View OriginalReply0
bbd®vip
· 2025-08-19 05:00
Just go for it💪
View OriginalReply0
bbd®vip
· 2025-08-19 05:00
Just go for it💪
View OriginalReply0
bbd®vip
· 2025-08-19 05:00
Just go for it💪
View OriginalReply0
bbd®vip
· 2025-08-19 05:00
Just go for it💪
View OriginalReply0